Importantly, this program, which entails activation of critical cancer-related pathways associated with cytoskeleton function, cell invasion and metastatic properties, while being enriched also in CRC tumors harboring DNA contact mutations at position R248 of p53, is not shared with R175 mutants. Here, TP53 is linked to cancer.